Your browser doesn't support javascript.
loading
Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention.
Koelmeyer, Louise A; Gaitatzis, Katrina; Dietrich, Mary S; Shah, Chirag S; Boyages, John; McLaughlin, Sarah A; Taback, Bret; Stolldorf, Deonni P; Elder, Elisabeth; Hughes, T Michael; French, James R; Ngui, Nicholas; Hsu, Jeremy M; Moore, Andrew; Ridner, Sheila H.
Afiliação
  • Koelmeyer LA; Australian Lymphoedema Education, Research, and Treatment (ALERT) Program, Faculty Medicine, Health & Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • Gaitatzis K; Australian Lymphoedema Education, Research, and Treatment (ALERT) Program, Faculty Medicine, Health & Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • Dietrich MS; Vanderbilt University School of Nursing, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Shah CS; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Boyages J; Australian Lymphoedema Education, Research, and Treatment (ALERT) Program, Faculty Medicine, Health & Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • McLaughlin SA; Icon Cancer Centre, Sydney, New South Wales, Australia.
  • Taback B; Mayo Clinic, Jacksonville, Florida, USA.
  • Stolldorf DP; Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
  • Elder E; Vanderbilt University School of Nursing, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Hughes TM; Westmead Breast Cancer Institute, Westmead, New South Wales, Australia.
  • French JR; The University of Sydney, Sydney, New South Wales, Australia.
  • Ngui N; Lakeside Specialist Breast Clinic, Norwest, New South Wales, Australia.
  • Hsu JM; ANU Clinical School at Sydney Adventist Hospital, Australian National University, Canberra, Australia.
  • Moore A; Westmead Breast Cancer Institute, Westmead, New South Wales, Australia.
  • Ridner SH; The University of Sydney, Sydney, New South Wales, Australia.
Cancer ; 128(18): 3408-3415, 2022 09 15.
Article em En | MEDLINE | ID: mdl-35797441
ABSTRACT

BACKGROUND:

To evaluate risk factors (treatment-related, comorbidities, and lifestyle) for breast cancer-related lymphedema (BCRL) within the context of a Prospective Surveillance and Early Intervention (PSEI) model of care for subclinical BCRL.

METHODS:

The parent randomized clinical trial assigned patients newly diagnosed with breast cancer to PSEI with either bioimpedance spectroscopy (BIS) or tape measurement (TM). Surgical, systemic and radiation treatments, comorbidities, and lifestyle factors were recorded. Detection of subclinical BCRL (change from baseline of either BIS L-Dex ≥6.5 or tape volume ≥ 5% and < 10%) triggered an intervention with compression therapy. Volume change from baseline ≥10% indicated progression to chronic lymphedema and need for complex decongestive physiotherapy. In this secondary analysis, multinomial logistic regressions including main and interaction effects of the study group and risk factors were used to test for factor associations with outcomes (no lymphedema, subclinical lymphedema, progression to chronic lymphedema after intervention, progression to chronic lymphedema without intervention). Post hoc tests of significant interaction effects were conducted using Bonferroni-corrected alphas of .008; otherwise, an alpha of .05 was used for statistical significance.

RESULTS:

The sample (n = 918; TM = 457; BIS = 461) was female with a median age of 58.4 years. Factors associated with BCRL risk included axillary lymph node dissection (ALND) (p < .001), taxane-based chemotherapy (p < .001), regional nodal irradiation (RNI) (p ≤ .001), body mass index >30 (p = .002), and rurality (p = .037). Mastectomy, age, hypertension, diabetes, seroma, smoking, and air travel were not associated with BCRL risk.

CONCLUSIONS:

Within the context of 3 years of PSEI for subclinical lymphedema, variables of ALND, taxane-based chemotherapy, RNI, body mass index >30, and rurality increased risk.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Linfedema Relacionado a Câncer de Mama / Linfedema Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Linfedema Relacionado a Câncer de Mama / Linfedema Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália